PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media288344ArticlesСтатьиResearch ArticleNOVYE VOZMOZhNOSTI LEChENIYa PATsIENTOV S POYaSNIChNOY BOL'YuНОВЫЕ ВОЗМОЖНОСТИ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ПОЯСНИЧНОЙ БОЛЬЮKamchatnovP. RКамчатновП. Р

д.м.н., проф., кафедра неврологии, нейрохирургии и медицинской генетики лечебного факультета

pavkam7@gmail.comUmarovaKh. YaУмароваХ. Я

д.м.н., проф. кафедры пропедевтики нервных болезней медицинского факультета

ChugunovA. VЧугуновА. В

к.м.н., доцент кафедры неврологии, нейрохирургии и медицинской генетики лечебного факультета

ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииГБОУ ВПО «Чеченский государственный университет»101020152219NO19 (2015)№19 (2015)343826022023Copyright ©; 2015, Bionika MediaCopyright ©; 2015, ООО «Бионика Медиа»2015Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/288344

Low back pain (LBP) is a common clinical syndrome characterized by frequent recurrence associated with the risk of disability and significant material costs. Serious problems of treating patients with LBP include formation of chronic pain and the risk of complications of therapy. The possibility of use of diacerein in patients with LBP is of considerable interest; clinical effects of this drug are realized primarily by inhibiting the activity of interleukin-1. The results of experimental and clinical studies on the effectiveness and tolerability of the drug in patients with articular pathology are discussed.

Поясничная боль (ПБ) - распространенный клинический синдром, характеризующийся частым рецидивированием, ассоциированный с риском утраты трудоспособности и значительными материальными затратами. Серьезными проблемами лечения пациентов с ПБ является формирование хронического болевого синдрома и высокая вероятность развития осложнений проводимой терапии. Значительный интерес представляет возможность применения больными ПБ препарата диацереин, клинические эффекты которого реализуются в первую очередь за счет угнетения активности интерлейкина-1. Рассматриваются результаты экспериментальных и клинических исследований, посвященных эффективности применения препарата пациентами с суставной патологией и его переносимости.

low back painosteoarthrosisdiacereinпоясничная больостеоартроздиацереинBuchbinder R., Blyth F., March L., Brooks P., Woolf A.D., Hoy D.G. Placing the global burden of low back pain in context. Best. Pract. Res. Clin. Rheumatol. 2013; 27(5): 575-89.Vos T., Flaxman A., Naghavi M. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2163-96.Hoy D., Bain C., Williams G. A systematic review of the global prevalence of low back pain. Arthritis Rheum. 2012; 64(6): 2028-37.Gore M., Sadosky A., Stacey B., Tai K.S, Leslie D. The burden of chronic low back pain: clinical comorbidities, treatment patterns, and health care costs in usual care settings. Spine (Phila Pa 1976). 2012; 37(11): E668-E677.Sadosky A., Taylor-Stokes G., Lobosco S., Pike J., Ross E. Relationship between self-reported low-back pain severity and other patient-reported outcomes: results from an observational study. J. Spinal. Disord. Tech. 2013; 26(1): 8-14.Suka M., Yoshida K. Musculoskeletal pain in Japan: prevalence and interference with daily activities. Mod. Rheumatol. 2005; 15(1): 41-7.Maataoui A., Vogl J., Middendorp M., Kafchitsas K., Khan M.F. Association between facet joint osteoarthritis and the Oswestry Disability index. World. J. Radiol. 2014; 6(11): 881-85.Suri P., Hunter D., Rainville J., Guermazi A., Katz J.N. Presence and Extent of Severe Facet Joint Osteoarthritis Are Associated with Back Pain in Older Adults. Osteoarthritis Cartilage. 2013; 21(9): 1199-206.Lanas A., Boers М., Nuevo J. Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAiDs) for rheumatic diseases: the EViDENCE study of European routine practice. Ann. Rheum. Dis. 2015; 74: 675-81.Rianon N., Knell M., Agbor-Bawa W., Thelen J. Persistent nonmalignant pain management using nonsteroidal anti-inflammatory drugs in older patients and use of inappropriate adjuvant medications. Drug, Healthcare and Patient Safety 2015; 7: 43-50.Bruy'ere O., Burlet N., Delmas P.D., Rizzoli R., Cooper C., Reginster J.Y. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskeletal Disorders. 2008; 9: 165.Spencer C.M., Wilde M.i. Diacerein. Drugs. 1997; 53(1): 98-108.de isla N.G., Mainard D., Muller S., Stoltz J.F. in vitro effects of diacerein on NO production by chondrocytes in response to proinflammatory mediators. Bio-Medical Materials and Engineering. 2008; 18(1): 99-104.Tamura T., Kosaka N., Ishiwa J., Sato T., Nagase H., Ito A. Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. Osteoarthritis and Cartilage. 2001; 9(3): 257-63.Douni E., Sfikakis P., Haralambous S., Fernandes P. Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res. Ther. 2004; 6(1): 65-72.Moldovan F., Pelletier J., Jolicoeur F., Cloutier J.M., Martel-Pelletier J. Diacerhein and rhein reduce the iCE-induced iL-1beta and iL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cartilage. 2000; 8: 186-96.Martel-Pelletier J., Mineau F., Jolicoeur F., Cloutier J.M., Pelletier J.P. in vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol. 1998; 25: 753-62.Moore A., Greenslade K., Alam C., Willoughby D. Effects of diacerhein on granuloma induced cartilage breakdown in the mouse. Osteoarthritis Cartilage. 1998; 6: 19-23.Smith G., Myers S., Brandt K., Mickler E.A., Albrecht M.E. Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis Rheum. 1999; 42: 545-54.Carney S. Effect of diacetyl rhein on the development of experimental osteoarthritis. A biochemical investigation. Osteoarthritis Cartilage. 1996; 4: 251-61.Brandt K., Smith G., Kang S., Myers S., O’Connor B., Albrecht M. Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthritis Cartilage. 1997; 5: 438-49.Tamura T., Ohmori K., Nakamura K. Effect of diacerein on spontaneous polyarthritis in male New Zealand black/KN mice. Osteoarthritis Cartilage. 1999; 7: 533-38.Felisaz N., Boumediene K., Ghayor C. Stimulating effect of diacerein on TGF-ß 1 and ß2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthritis and Cartilage. 1999; 7; 3: 255-67.Pujol J.P., Felisaz N., Boumediene K. Effects of diacerein on biosynthesis activities of chondrocytes in culture. Biorheology. 2000; 37(1-2): 177-84.Suwannaloet W., Laupattarakasem W., Sukon P., Ong-Chai S., Laupattarakasem P. Combined Effect of Subchondral Drilling and Hyaluronic Acid with / without Diacerein in Full-Thickness Articular Cartilage Lesion in Rabbits. Scientific World J. 2012; 310745. doi: 10.1100/2012/310745.Brahmachari B., Chatterjee S., Ghosh A. Efficacy and safety of diacerein in early knee osteoarthritis: a randomized placebo-controlled trial. Clinical Rheumatology. 2009; 28(10): 1193-98.Louthrenoo W., Nilganuwong S., Aksaranug-Raha S., Asavatanabodee P., Saengnipanthkul S.; Thai Study Group. The efficacy, safety and carryover effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, doubleblind, NSAiD-controlled study. Osteoarthritis and Cartilage 2007; 15(6): 605-14.Rintelen B., Neumann K., Leeb B.F. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Archives of internal Medicine. 2006; 166(17): 1899-906.Shin K., Kim J., Moon K., et al. The efficacy of diacerein in hand osteoarthritis: a double-blind, randomized, placebo-controlled study. Clin. Ther. 2013; 35(4): 431-39.Dougados M., Nguyen M., Berdah L., Vignon E., Lequesne M., et al. ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum. 2001; 44(11): 2539-47.Madry H., Grün U., Knutsen G. Cartilage repair and joint preservation: medical and surgical treatment options. Dtsch. Arztebl. Int. 2011; 108(40): 669-77.Steinmeyer J., Konttinen Y. Oral treatment options for degenerative joint disease-presence and future. Adv. Drug. Deliv. Rev. 2006; 58: 168-211.Bartels E., Bliddal H., Schöndorff P., Altman R.D., Zhang W., Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage. 2010; 18: 289-96.Лапшина С.А., Мясоутова Л.И., Салихов И.Г., Васильев А.Г. Оценка эффективности и безопасности препарата артрокер (диацерени) у пациентов с остеоартрозом коленного сустава. Современное искусство медицины. http://artmedicine.ru/articles/klinicheskij_razdel/41/.Заигрова Н.К. Оценка эффективности препарата Артрокер при остеоартрозе коленных суставов. Современная ревматология. 2013; (4): 23-5.Балабанова Р.М. Роль интерлейкина-1 при остеоартрозе и возможности его блокирования. Современная ревматология. 2011; 1: 58-63.Fidelix T., Macedo C., Maxwell L., Fernandes Moca Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst. Rev. 2014; 2: CD005117. doi: http://dx.doi.org/10.1002/14651858.CD005117.pub3Assessment report for diacerein containing medicinal products. 28 August 2014 EMA/527347/2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diacerein/ European_Commission_final_decision/WC500173144.pdfКаратеев А.Е. Достоинства и недостатки диацереина. Современная ревматология. 2014; 4: 90-5.